Table 1 Cytotoxic activities of the synthesized compounds.

From: Synthesis, antimicrobial, anti-inflammatory, antioxidant and cytotoxicity of new pyrimidine and pyrimidopyrimidine derivatives

Comp.

In vitro Cytotoxicity IC50 (µM) •

WI38

HCT116

HePG2

MCF7

DOX

6.72 ± 0.5

5.23 ± 0.3

4.50 ± 0.2

4.17 ± 0.2

3a

63.29 ± 3.6

15.91 ± 1.2

26.17 ± 2.0

11.14 ± 0.9

3b

75.21 ± 3.9

9.15 ± 0.7

13.20 ± 1.1

7.58 ± 0.6

3c

48.54 ± 2.9

35.46 ± 2.4

54.51 ± 3.1

23.99 ± 1.8

3d

57.29 ± 3.3

61.33 ± 3.5

32.87 ± 2.3

46.49 ± 2.6

10a

63.67 ± 3.3

21.58 ± 1.7

25.06 ± 1.9

10.66 ± 0.8

10b

35.67 ± 2.4

13.92 ± 1.0

8.32 ± 0.7

7.81 ± 0.5

10c

42.33 ± 2.6

9.16 ± 0.6

6.81 ± 0.4

5.62 ± 0.3

11a

28.12 ± 2.2

74.34 ± 3.7

65.87 ± 3.4

45.91 ± 2.9

11b

85.07 ± 4.3

37.16 ± 2.5

32.87 ± 2.3

27.83 ± 2.2

11c

50.31 ± 2.9

83.91 ± 4.2

71.36 ± 3.8

68.51 ± 3.2

  1. • IC50 (µM): 1–10 (very strong). 11–20 (strong). 21–50 (moderate). 51–100 (weak) and above 100 (non-cytotoxic).
Back to article page